简介: 【摘要】 目的:探讨并分析多巴丝肼片(美多巴)联合盐酸普拉克索速释片治疗帕金森的临床效果及安全性。方法:此次研究的对象是选取笔者所在医院 2015年 5月 -2016年 7月收治的 78例帕金森病患者,将其临床资料进行回顾性分析,并采用随机数字法将其均分为对照组和观察组,每组 39例。对照组患者采用美多巴治疗,观察组患者采用美多巴联合盐酸普拉克索速释片治疗,比较两组患者治疗后的临床效果及不良反应发生率。结果:观察组的治疗总有效率 87%,明显高于对照组的 62%,差异有统计学意义(字 2=6.72, P<0.05);观察组的不良反应发生率 5%,明显低于对照组的 23%,差异有统计学意义(字 2=5.19, P<0.05)。结论:美多巴联合盐酸普拉克索速释片治疗帕金森病的临床效果显著,是值得在临床上推广使用的安全可靠的治疗方法。 【关键词】 帕金森病; 多巴丝肼片; 盐酸普拉克索速释片; 临床疗效; 安全性 Objective: To explore and analyze the clinical efficacy and safety of the treatment of Parkinson with the combination of the tablets and the fast release tablets of pramipexole hydrochloride. Methods: the object of this study was to select 78 cases of Parkinson's disease in the hospital of my hospital in July -2016 May 2015. The clinical data of the patients were analyzed retrospectively, and they were divided into the control group and the observation group by random number method, with 39 cases in each group. The patients in the control group were treated with methada, and the patients in the observation group were treated with the combination of methyopa and pramc. The clinical effect and the incidence of adverse reactions were compared between the two groups. Results: the total effective rate of treatment in the observation group was 87%, which was significantly higher than that of the control group (62%). The difference was statistically significant (word 2=6.72, P<0.05); the incidence of adverse reactions in the observation group was 5%, which was significantly lower than that of the control group (23%). The difference was statistically significant (word 2=5.19, P<0.05). Conclusion: the clinical effect of the combined treatment of dopa and pramopexo in the treatment of Parkinson's disease is significant. It is a safe and reliable method to be used in clinical practice.